David Sermer

ORCID

Publication Activity (10 Years)

Years Active: 2022-2023
Publications (10 Years): 4

Top Venues

Leukemia & lymphoma

Expert review of anticancer therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Hoa Van Le, Kim Van Naarden Braun, Grzegorz S Nowakowski, David Sermer, John Radford, William Townsend, Hervé Ghesquières, Tobias Menne, Edit Porpaczy, Christopher P Fox, Claudia Schusterbauer, Fei Fei Liu, Lihua Yue, Marc De Benedetti, Jens Hasskarl
Use of a real-world synthetic control arm for direct comparison of lisocabtagene maraleucel and conventional therapy in relapsed/refractory large B-cell lymphoma. Leukemia & lymphoma 64 (3) (2023)
Hoa Van Le, Kim Van Naarden Braun, Grzegorz S Nowakowski, David Sermer, John Radford, William Townsend, Hervé Ghesquières, Tobias Menne, Edit Porpaczy, Christopher P Fox, Claudia Schusterbauer, Fei Fei Liu, Lihua Yue, Marc De Benedetti, Jens Hasskarl
Use of a real-world synthetic control arm for direct comparison of lisocabtagene maraleucel and conventional therapy in relapsed/refractory large B-cell lymphoma. Leukemia & lymphoma 64 (3) (2023)
Hoa Van Le, Kim Van Naarden Braun, Grzegorz S Nowakowski, David Sermer, John Radford, William Townsend, Hervé Ghesquières, Tobias Menne, Edit Porpaczy, Christopher P Fox, Claudia Schusterbauer, Fei Fei Liu, Lihua Yue, Marc De Benedetti, Jens Hasskarl
Use of a real-world synthetic control arm for direct comparison of lisocabtagene maraleucel and conventional therapy in relapsed/refractory large B-cell lymphoma. Leukemia & lymphoma (2023)
Shayna R Sarosiek, David Sermer, Andrew R Branagan, Steven P Treon, Jorge J Castillo
Zanubrutinib for the treatment of adults with Waldenstrom macroglobulinemia. Expert review of anticancer therapy 22 (5) (2022)

David Sermer.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

David Sermer